Pliant Therapeutics (PLRX) Stock: Buy, Sell, or Hold?
PLRX - Pliant Therapeutics, Inc. Common Stock
$0.87
-0.02 (-2.31%)
▼
5d:
-11.01%
30d:
-23.08%
90d:
-20.61%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When PLRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PLRX is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PLRX is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PLRX is currently trading at $0.87, which is considered oversold relative to its 30-day fair value range of $0.94 to $1.12.
Technical Outlook: Technically, PLRX is in a downtrend. The price is currently testing key support at $0.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PLRX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.00 (+131.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLRX is in a downtrend. The price is currently testing key support at $0.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PLRX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.00 (+131.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.94 -
$1.12
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 131.1% below Wall St target ($2.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.94 -
$1.12
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.85
Resistance Level
$1.03
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.67
Wall Street Target
$2.00
(+131.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 22, 2026 7:56 PM ET
Data refreshes hourly during market hours. Next update: 8:56 PM
Data refreshes hourly during market hours. Next update: 8:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 68 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 62 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 71 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 44 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 60 HOLD |
